摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(+/-)-9-Ethyl-4-oxo-2-pyrimidin-4-yl-5,6,8,9-tetrahydro-4H-1,4a,7-triazabenzocycloheptene-7-carboxylic acid ethyl ester | 1202692-53-2

中文名称
——
中文别名
——
英文名称
(+/-)-9-Ethyl-4-oxo-2-pyrimidin-4-yl-5,6,8,9-tetrahydro-4H-1,4a,7-triazabenzocycloheptene-7-carboxylic acid ethyl ester
英文别名
(+/-)-9-Ethyl-4-oxo-2-pyrimidin-4-yl-5,6,8,9-tetrahydro-4H-1,4-a,7-triaza-benzocycloheptene-7-carboxylic acid ethyl ester;ethyl 10-ethyl-4-oxo-2-pyrimidin-4-yl-6,7,9,10-tetrahydropyrimido[1,2-d][1,4]diazepine-8-carboxylate
(+/-)-9-Ethyl-4-oxo-2-pyrimidin-4-yl-5,6,8,9-tetrahydro-4H-1,4a,7-triazabenzocycloheptene-7-carboxylic acid ethyl ester化学式
CAS
1202692-53-2
化学式
C17H21N5O3
mdl
——
分子量
343.385
InChiKey
QJPHPTYEASALNF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.3
  • 重原子数:
    25
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.47
  • 拓扑面积:
    88
  • 氢给体数:
    0
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (+/-)-9-Ethyl-4-oxo-2-pyrimidin-4-yl-5,6,8,9-tetrahydro-4H-1,4a,7-triazabenzocycloheptene-7-carboxylic acid ethyl ester氢溴酸溶剂黄146 作用下, 反应 4.0h, 以88%的产率得到(+/-)-9-ethyl-2-pyrimidin-4-yl-6,7,8,9-tetrahydro-5h-1,4a,7-triazabenzocyclohepten-4-one hydrobromide
    参考文献:
    名称:
    Substituted alkyl pyrimidin-4-one derivatives
    摘要:
    本发明涉及一种由式(I)表示的吡啶酮衍生物或其盐、溶剂或水合物:其中:X代表亚甲基、NH、氮原子,其上取代有C(O)-O-(C1-6-烷基)基团;R1代表2、3或4-吡啶环或2、4或5-嘧啶环,该环可选地取代有C1-6烷基、C1-6烷氧基或卤素原子;R2代表氢原子、C1-6烷基或卤素原子;R3代表可选的C1-6烷基取代基;R4代表氢原子、卤素原子、羟基、C1-6烷基;m当X为亚甲基时为1-2,当X为NH、氮原子上取代有C(O)-O-(C1-6-烷基)基团时为2;以自由碱或与酸的加成盐的形式使用于治疗。
    公开号:
    EP2138494A1
  • 作为产物:
    描述:
    5-amino-2,3,6,7-tetrahydro-[1,4]diazepine-1-carboxylic acid ethyl ester monohydrochloride碘乙烷lithium hexamethyldisilazane 作用下, 以 四氢呋喃 为溶剂, 反应 3.17h, 以18%的产率得到(+/-)-9-Ethyl-4-oxo-2-pyrimidin-4-yl-5,6,8,9-tetrahydro-4H-1,4a,7-triazabenzocycloheptene-7-carboxylic acid ethyl ester
    参考文献:
    名称:
    Substituted alkyl pyrimidin-4-one derivatives
    摘要:
    本发明涉及一种由式(I)表示的吡啶酮衍生物或其盐、溶剂或水合物:其中:X代表亚甲基、NH、氮原子,其上取代有C(O)-O-(C1-6-烷基)基团;R1代表2、3或4-吡啶环或2、4或5-嘧啶环,该环可选地取代有C1-6烷基、C1-6烷氧基或卤素原子;R2代表氢原子、C1-6烷基或卤素原子;R3代表可选的C1-6烷基取代基;R4代表氢原子、卤素原子、羟基、C1-6烷基;m当X为亚甲基时为1-2,当X为NH、氮原子上取代有C(O)-O-(C1-6-烷基)基团时为2;以自由碱或与酸的加成盐的形式使用于治疗。
    公开号:
    EP2138494A1
点击查看最新优质反应信息

文献信息

  • SUBSTITUTED ALKYL PYRIMIDIN-4-ONE DERIVATIVES
    申请人:FAYOL Aude
    公开号:US20110144092A1
    公开(公告)日:2011-06-16
    A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: wherein X, R1, R2, R3, R4, and m are defined in the disclosure. Also disclosed are methods of preparing the compounds of formula (I), intermediates thereof and their use in therapeutics.
    一种由式(I)表示的吡啶酮衍生物或其盐、溶剂或水合物:其中X,R1,R2,R3,R4和m在本文中有定义。还公开了制备式(I)化合物的方法,其中间体及其在治疗中的用途。
  • JP2011525908A
    申请人:——
    公开号:JP2011525908A
    公开(公告)日:2011-09-29
  • [EN] SUBSTITUTED ALKYL PYRIMIDIN-4-ONE DERIVATIVES<br/>[FR] DÉRIVÉS PYRIMIDIN-4-ONE À SUBSTITUTION ALKYLE
    申请人:MITSUBISHI TANABE PHARMA CORP
    公开号:WO2009156864A2
    公开(公告)日:2009-12-30
    A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof (I), wherein, X represents a methylene, NH, a nitrogen atom substituted by a C(O)-O- (C1-6-alkyl) group; R1 represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring, the ring being optionally substituted by a C1-6 alkyl group, a C1-6 alkoxy group or a halogen atom; R2 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; R3 represents a C1-6 alkyl group optionally substituted, R4 represents a hydrogen atom, a halogen atom, a hydroxyl group, a C1-6 alkyl group; m represents 1 to 2 when X is a methylene or m represents 2 when X is NH, a nitrogen atom substituted by a C(O)-O-(C1-6-alkyl) group; in the form of a free base or of an addition salt with an acid. Use in therapeutic
  • Substituted alkyl pyrimidin-4-one derivatives
    申请人:Sanofi-Aventis
    公开号:EP2138494A1
    公开(公告)日:2009-12-30
    A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: wherein : X represents a methylene, NH, a nitrogen atom substituted by a C(O)-O-(C1-6-alkyl) group; R1 represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring, the ring being optionally substituted by a C1-6 alkyl group, a C1-6 alkoxy group or a halogen atom; R2 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; R3 represents a C1-6 alkyl group optionally substituted, R4 represents a hydrogen atom, a halogen atom, a hydroxyl group, a C1-6 alkyl group; m represents 1 to 2 when X is a methylene or m represents2 when X is NH, a nitrogen atom substituted by a C(O)-O-(C1-6-alkyl) group ; in the form of a free base or of an addition salt with an acid. Use in therapeutic
    本发明涉及一种由式(I)表示的吡啶酮衍生物或其盐、溶剂或水合物:其中:X代表亚甲基、NH、氮原子,其上取代有C(O)-O-(C1-6-烷基)基团;R1代表2、3或4-吡啶环或2、4或5-嘧啶环,该环可选地取代有C1-6烷基、C1-6烷氧基或卤素原子;R2代表氢原子、C1-6烷基或卤素原子;R3代表可选的C1-6烷基取代基;R4代表氢原子、卤素原子、羟基、C1-6烷基;m当X为亚甲基时为1-2,当X为NH、氮原子上取代有C(O)-O-(C1-6-烷基)基团时为2;以自由碱或与酸的加成盐的形式使用于治疗。
查看更多

同类化合物

阿斯普尼辛B 阿斯普尼辛 D 阿斯普尼辛 苯佐莫文 新骏河毒素 乙酰胺,N-(4-硝基-2-吡啶基)-,氧化(9CI) TAK960抑制剂 PLK1抑制剂(RO3280) 8H-嘧啶并[4,5-b][1,4]二氮杂卓 8-甲基-5,9-二氢-6H-嘧啶并[4,5-b][1,4]重氮基庚英-6-酮 6H-嘧啶并[4,5-b][1,4]二氮杂卓 4-甲基-6,11-二氢-3H-嘧啶并[4,5-b][1,5]苯并二氮杂卓-2,5-二酮 2-氯-7,7-二氟-5-甲基-5,7,8,9-四氢-6H-嘧啶基[4,5-B][1,4]二氮杂-6-酮 2-氯-5-甲基-5,7,8,9-四氢-6H-嘧啶[4,5-B][1,4]二氮杂6-酮 1H-嘧啶并[4,5-b][1,4]二氮杂卓 4-amino-8-(1,3-benzodioxol-5-yl)-6-phenyl-8,9-dihydro-7H-pyrimido[4,5-b][1,4]diazepine 2-(2-Bromo-4-isopropyl-phenyl)-4-methyl-6-pentyl-6,7,8,9-tetrahydro-2H-2,3,5,6,9a-pentaaza-benzo[cd]azulen-1-one 2-chloro-8-(trifluoromethyl)-6H,11H-benzo[b]pyrimidino[5,4-f]-1,4-diazaperhydroepin-5-one 4,5,6,7-tetrahydro-2,4-diphenyl-4,7a,12b-triazadibenzo[e,g]azulene-1,3,8-trione 4,5,6,7-tetrahydro-4-methyl-2-phenyl-4,7a,12b-triazadibenzo[e,g]azulene-1,3,8-trione N-(4-((8,9-dimethoxy-5-methyl-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-11H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-5-methyl-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-fluorophenyl)-N-(4-((8-methoxy-2-methyl-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-fluorophenyl)-N-(4-((8-methoxy-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-11H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide di-tert-butyl (1r,4r)-4-(4-(9-cyclohexyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxybenzamido)cyclohexyl phosphate 2-(2-Bromo-4-isopropyl-phenyl)-6-(1-ethyl-propyl)-4-methyl-6,7,8,9-tetrahydro-2H-2,3,5,6,9a-pentaaza-benzo[cd]azulen-1-one 7,8,9,10-tetrahydro-10-hydroxy-9-heptyl-[1,4]diazepino[1,2,3-g,h]purine 7,8,9,10-tetrahydro-10-hydroxy-9-methyl-9-propyl[1,4]diazepino[1,2,3-g,h]purine 6-cyclopentyl-9-[(3-methoxyphenyl)amino]-2-methyl-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-3-one 6-cyclopentyl-9-[(2-methoxyphenyl)amino]-2-methyl-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-3-one tert-butyl 8,10-dibromo-7-oxo-1,2,5,5a,6,7-hexahydro-[1,4]diazepino[1,7-a]quinazoline-3(4H)-carboxylate tert-butyl 8,10-dimethyl-7-oxo-1,2,5,5a,6,7-hexahydro-[1,4]diazepino[1,7-a]quinazoline-3(4H)-carboxylate 11-Diallylaminoacetyl-6-isopropyl-5,6-dihydropyrimido[4,5-b][1,5]benzodiazepin-5-one 6-butyl-11-diallylaminoacetyl-2-phenyl-5,6-dihydropyrimido[4,5-b][1,5]benzodiazepin-5-one 11-chloroacetyl-6-isopropyl-5,6-dihydropyrimido[4,5-b][1,5]benzodiazepin-5-one 4-[(2-cyclopentyl-4,4,6-trimethyl-5-oxo-2,6,9,11-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-10-yl)amino]benzoic acid 4-[(2-cyclopentyl-6-methyl-5-oxo-2,6,9,11-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-10-yl)amino]-3-methoxy-N-(4-piperidyl)benzamide 4-[(6-cyclopentyl-2-methyl-3-oxo-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-9-yl)amino]-N-(1-ethyl-4-piperidyl)-3-methoxy-benzamide 8-(4-chlorophenyl)-6-phenyl-9H-pyrimido[4,5-b][1,4]diazepin-4-ol 1-chloro-7-methoxy-8-(3-morpholin-4-yl-propoxy)-10,11-dihydro-5H-2,4,5,11-tetraaza-dibenzo[a,d]cycloheptene 4-[(6-cyclopentyl-2-methyl-3-oxo-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-9-yl)amino]-3-methoxy-N-methyl-benzamide (S)-tert-butyl (4-chloro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-7-yl)carbamate 3-methoxy-4-[[6-(2-methoxyethyl)-2-methyl-3-oxo-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-9-yl]amino]-N-(1-methyl-4-piperidyl)benzamide (9aS,9R)-4-chloro-N-(4-methylphenyl)-9a,10,11,12-tetrahydro-9H-pyrimido[4,5-b]dipyrrolo[1,2-d:2',1'-g][1,4]diazepin-9-amine